DIABETES MELLITUS-ALPHA-GLUCOSIDASE INHIBITORS

From NeuroRehab.wiki

Revision as of 11:07, 20 March 2023 by Dr Appukutty Manickam (talk | contribs) (Imported from text file)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

SUMMARY

1. AGI delay carbohydrate absorption in the gut.

2. Representatives: acarbose and miglitol.

3. Biggest effect is on post-prandial glucose.

4. Common side effects: flatulence, diarrhea, abdominal bloating.

5. AGls are approved for monotherapy and in combination with sulfonylureas (glipizide).


Reference(s)

Wilkinson, I., Furmedge, D. and Sinharay, R. (2017). Oxford handbook of clinical medicine. Oxford: Oxford University Press. Get it on Amazon.
Feather, A., Randall, D. and Waterhouse, M. (2020). Kumar And Clark’s Clinical Medicine. 10th ed. S.L.: Elsevier Health Sciences. Get it on Amazon.
Hannaman, R. A., Bullock, L., Hatchell, C. A., & Yoffe, M. (2016). Internal medicine review core curriculum, 2017-2018. CO Springs, CO: MedStudy.
Therapeutic Guidelines. Melbourne: Therapeutic Guidelines Limited. https://www.tg.org.au [Accessed 2021].

Retrieved from "https://www.neurorehab.wiki/index.php?title=DIABETES_MELLITUS-ALPHA-GLUCOSIDASE_INHIBITORS&oldid=19082"